Orchestra BioMed Announces Initiation of BACKBEAT Pivotal Study of AVIM Therapy in Hypertensive Pacemaker Patients
08 janv. 2024 07h30 HE
|
Orchestra BioMed
Orchestra BioMed and Medtronic, Inc., have an exclusive strategic collaboration for development and commercialization of AVIM therapy for hypertensive pacemaker population, which is estimated to be...
Orchestra BioMed to Present at Upcoming Investor Conferences
09 nov. 2023 16h42 HE
|
Orchestra BioMed
NEW HOPE, Pa., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to...
Orchestra BioMed™ Announces Presentation of Positive Long-Term Clinical Results from MODERATO II Control Patients Crossover Extension Study of BackBeat CNT™ at TCT 2022
20 sept. 2022 08h00 HE
|
Orchestra BioMed
NEW HOPE, Pa., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Orchestra BioMed™, Inc., (“Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact technologies to patients...
Orchestra BioMed™ Announces Strategic Collaboration, Closing of $110 Million Private Equity Financing and Plans to List on Nasdaq Through Merger with Health Sciences Acquisitions Corporation 2
05 juil. 2022 08h00 HE
|
Orchestra BioMed
Strategic collaboration with Medtronic to develop BackBeat Cardiac Neuromodulation Therapy™ as potential integrated hypertension treatment for cardiac pacemaker patients Investors in $110...
Orchestra BioMed™ Announces Presentations at TCT 2021 of Positive Long-Term Clinical Results from the MODERATO II Study Showing the Significant Clinical Impact of BackBeat CNT™ on Isolated Systolic Hypertension and Pulse Pressure
05 nov. 2021 08h00 HE
|
Orchestra BioMed
BackBeat CNT treated patients experienced a mean reduction of 17.5 mmHg in office systolic blood pressure measured 24-months following therapy activation. Patients with Isolated Systolic Hypertension...
Orchestra BioMed™ Announces Peer-Reviewed Publication of MODERATO II Study Results Showing a Statistically Significant Reduction in Blood Pressure in Pacemaker-Indicated Patients Treated with BackBeat Cardiac Neuromodulation Therapy™
17 août 2021 08h00 HE
|
Orchestra BioMed
Double-blind, randomized trial data show a clinically meaningful and statistically significant net reduction of 8.1 mmHg in 24-hour ambulatory systolic blood pressure at 6 months in treated vs....
Orchestra BioMed™ Announces Clinical Data Demonstrating a Significant and Sustained Reduction in Blood Pressure in MODERATO II Control Patients After Crossover to BackBeat Cardiac Neuromodulation Therapy™
30 juil. 2021 08h00 HE
|
Orchestra BioMed
Clinically meaningful and statistically significant reduction in systolic blood pressure is consistent with the decrease previously observed in the study treatment group during the same time period. ...
Orchestra BioMed™ Announces Clinical Data Showing Significant and Sustained Reduction in Systolic Blood Pressure Out to Two Years with BackBeat Cardiac Neuromodulation Therapy™
17 mai 2021 08h30 HE
|
Orchestra BioMed
Clinically meaningful and statistically significant reduction of 16.6 mmHg in systolic blood pressure out to two years 88% of the treated patients had isolated systolic hypertension (ISH) 70.6% of...
Orchestra BioMed™ Appoints Drug-Device Combination Expert Jagdish Parasrampuria as Vice President of Pharmaceutical Development
13 juil. 2020 08h00 HE
|
Orchestra BioMed
NEW HOPE, Pa., July 13, 2020 (GLOBE NEWSWIRE) -- Orchestra BioMed, Inc. (“Orchestra BioMed” or the “Company”), a biomedical innovation company focused on developing transformative therapeutic...
Orchestra BioMed™ Enhances Management Team with Appointment of Regulatory Affairs and Combination Product Expert Bob Laughner as Vice President, Regulatory Affairs
28 avr. 2020 08h00 HE
|
Orchestra BioMed
NEW HOPE, Pa., April 28, 2020 (GLOBE NEWSWIRE) -- Orchestra BioMed, Inc. (“Orchestra BioMed” or the “Company”), a biomedical innovation company developing transformative therapeutic products for...